Orion
41.63 EUR +0.46%13,764 investors are following this company
Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.
P/E (24e)
20.55
EV/EBIT (adj.) (24e)
16.48
P/B (24e)
6.18
Dividend yield-% (24e)
3.96 %
Target price
44.00 EUR
Recommendation
Accumulate
Updated
1.7.2024
NASDAQ Helsinki
ORNBV
Daily low / high price
41.16 / 42.48
EUR
Market cap
5.88B EUR
Turnover
13.22M EUR
Volume
316K
Business risk
Valuation risk
Current
Previous
Analyst
![Antti Siltanen Antti Siltanen](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://core.inderes.fi/sites/default/files/2023-08/Antti_Siltanen.jpg)
Antti Siltanen
Analyst
Latest videos
Financial calendar
Interim report
2024-08-08
Half year dividend
2024-10-15
Interim report
2024-10-29
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Ilmarinen Mutual Pension Insurance Company | 3.7 % | 5.2 % |
Erkki Etola and companies | 2.0 % | 6.5 % |
Premium
This content is for our Premium customers only.
Insider Transactions
Insider | Date | Total value |
---|---|---|
Mikael Silvennoinen | 2023-11-15 | 44,782EUR |
Mikael Silvennoinen | 2023-11-15 | 27,034EUR |
Premium
This content is for our Premium customers only.
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 1,078.1 | 1,041.1 | 1,340.6 | 1,189.6 | 1,432.5 | 1,447.7 | 1,577.6 | 1,704.7 |
growth-% | 2.6 % | -3.4 % | 28.8 % | -11.3 % | 20.4 % | 1.1 % | 9.0 % | 8.1 % |
EBITDA | 336.5 | 289.0 | 486.6 | 326.4 | 410.3 | 355.3 | 428.2 | 493.5 |
EBIT (adj.) | 280.1 | 243.3 | 439.6 | 274.9 | 361.8 | 311.3 | 378.6 | 443.2 |
EBIT | 280.1 | 243.3 | 439.6 | 274.9 | 361.8 | 311.3 | 378.6 | 443.2 |
Profit before taxes | 278.3 | 242.3 | 440.3 | 271.9 | 359.8 | 307.0 | 374.9 | 440.0 |
Net income | 219.9 | 193.8 | 349.5 | 216.8 | 284.6 | 242.5 | 296.2 | 347.6 |
EPS (adj.) | 1.57 | 1.38 | 2.49 | 1.54 | 2.03 | 1.73 | 2.11 | 2.47 |
growth-% | 9.9 % | -11.9 % | 80.3 % | -38.0 % | 31.3 % | -14.8 % | 22.1 % | 17.4 % |
Dividend | 1.50 | 1.50 | 1.60 | 1.62 | 1.65 | 1.70 | 1.75 | 1.80 |
Dividend ratio | 95.8 % | 108.7 % | 64.3 % | 105.0 % | 81.4 % | 98.5 % | 83.0 % | 72.7 % |
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | 31.2 % | 27.8 % | 36.3 % | 27.4 % | 28.6 % | 24.5 % | 27.1 % | 28.9 % |
EBIT-% (adj.) | 26.0 % | 23.4 % | 32.8 % | 23.1 % | 25.3 % | 21.5 % | 24.0 % | 26.0 % |
EBIT-% | 26.0 % | 23.4 % | 32.8 % | 23.1 % | 25.3 % | 21.5 % | 24.0 % | 26.0 % |
ROE | 29.1 % | 26.8 % | 43.1 % | 24.1 % | 31.0 % | 25.5 % | 30.0 % | 32.6 % |
ROI | 34.4 % | 29.5 % | 45.6 % | 24.9 % | 31.7 % | 26.5 % | 32.0 % | 35.9 % |
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (EUR) | 37.53 | 36.52 | 51.24 | 39.27 | 41.63 | 41.63 | 41.63 | 41.63 |
Shares | 140.5 | 140.5 | 140.5 | 140.5 | 140.5 | 140.5 | 140.5 | 140.5 |
Market cap | 5,271.6 | 5,129.7 | 7,197.3 | 5,516.0 | 5,847.5 | 5,847.5 | 5,847.5 | 5,847.5 |
Enterprise value | 5,085.8 | 4,940.3 | 7,078.7 | 5,609.3 | 5,962.9 | 5,918.5 | 5,899.2 | 5,841.4 |
EV/S | 4.7 | 4.7 | 5.3 | 4.7 | 4.2 | 4.1 | 3.7 | 3.4 |
EV/EBITDA | 15.1 | 17.1 | 14.5 | 17.2 | 14.5 | 16.7 | 13.8 | 11.8 |
EV/EBIT (adj.) | 18.2 | 20.3 | 16.1 | 20.4 | 16.5 | 19.0 | 15.6 | 13.2 |
EV/EBIT | 18.2 | 20.3 | 16.1 | 20.4 | 16.5 | 19.0 | 15.6 | 13.2 |
P/E (adj.) | 24.0 | 26.5 | 20.6 | 25.4 | 20.5 | 24.1 | 19.7 | 16.8 |
P/E | 24.0 | 26.5 | 20.6 | 25.4 | 20.5 | 24.1 | 19.7 | 16.8 |
P/B | 7.2 | 7.2 | 7.9 | 6.2 | 6.2 | 6.1 | 5.8 | 5.2 |
P/S | 4.9 | 4.9 | 5.4 | 4.6 | 4.1 | 4.0 | 3.7 | 3.4 |
Dividend yield | 4.0 % | 4.1 % | 3.1 % | 4.1 % | 4.0 % | 4.1 % | 4.2 % | 4.3 % |
Equity ratio | 65.6 % | 66.0 % | 60.4 % | 61.9 % | 60.8 % | 62.7 % | 63.9 % | 67.6 % |
Gearing ratio | -25.4 % | -26.5 % | -13.1 % | 10.5 % | 12.2 % | 7.4 % | 5.1 % | -0.5 % |
Quarter data
Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 277.9 | 289.6 | 301.0 | 321.1 | 1,189.6 | 308.5 | 323.9 | 374.6 | 425.5 |
EBITDA | 67.7 | 59.4 | 92.7 | 106.6 | 326.4 | 67.0 | 75.0 | 132.4 | 135.9 |
EBIT | 55.5 | 46.6 | 79.9 | 92.9 | 274.9 | 56.0 | 62.5 | 119.9 | 123.4 |
Profit before taxes | 55.1 | 45.8 | 78.5 | 92.5 | 271.9 | 54.9 | 62.2 | 119.6 | 123.1 |
Net income | 43.8 | 36.4 | 61.4 | 75.2 | 216.8 | 43.7 | 49.2 | 94.5 | 97.2 |
ShowingAll content types
Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Orion is developing the Finnish life science industry in a unique collaboration project
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025
Orion Corporation: Managers’ transactions – Ari Lehtoranta
Orion Corporation: Managers’ transactions – Maziar Mike Doustdar
Orion Corporation: Managers’ transactions – Karen Lykke Sørensen
Orion Corporation: Managers’ transactions – Eija Ronkainen
Orion Corporation: Managers’ transactions – Henrik Stenqvist
Orion Corporation: Managers’ transactions – Kari Jussi Aho
Orion Corporation: Managers’ transactions – Hilpi Rautelin
Orion Corporation: Managers’ transactions – Veli-Matti Mattila
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Composition of the Nomination Committee of Orion Corporation
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
![Orion Oyj, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/8c0e7d23-2421-4cf7-9a60-8b60a088d457.png)